NUP170 Antibody

What is NUP170 and what is its cellular function?

NUP170 is a major nucleoporin that forms part of the inner ring of the nuclear pore complex (NPC). It plays essential roles in nuclear pore formation and maintenance, nucleocytoplasmic transport, and gene regulation. NUP170 has a structural homolog called NUP157, though they're not entirely redundant in function. In yeast, NUP170 comprises more than one-fifth of the mass of the isolated NPC when combined with NUP157, POM152, NUP188, and NIC96 . Functionally, NUP170 is implicated in maintaining proper stoichiometry of FG nucleoporins within the NPC and specifically localizing certain FG nucleoporins such as NUP1 and NUP2 . Recent research has also established NUP170's role in subtelomeric gene silencing through mechanisms involving chromatin organization .

What is the structural organization of NUP170?

NUP170 adopts a distinctive crescent moon shape and consists of two structurally distinct and separable domains:

• An N-terminal β-propeller domain: Functions primarily to recruit or retain specific nucleoporins including NUP159, NUP188, and POM34 at nuclear pores .

• A C-terminal α-solenoid domain: Serves as the anchoring region that secures NUP170 to the nuclear pore complex .

This structural organization is critical for understanding experimental results involving domain-specific antibodies or when designing experiments targeting specific functional regions of NUP170.

What phenotypes are observed when NUP170 is deleted or depleted?

While deletion of NUP170 alone (nup170Δ) is not lethal due to functional redundancy with other nucleoporins, several distinct phenotypes can be observed:

• Reduced number of nuclear pores (0.54 ± 0.03 pores/μm in wild-type conditions to approximately 0.25 pores/μm after NUP170 depletion)

• Loss of subtelomeric gene silencing, resulting in increased expression of subtelomeric genes such as COS4, COS10, GIT1, and TOG1

• Reduced PCNA levels on chromatin

• Morphological abnormalities in the nuclear envelope structure

• Synthetic lethality when combined with deletion of other nucleoporins (NUP157, NUP188) or the pore membrane protein POM152

When designing experiments using NUP170 antibodies in knockout or knockdown systems, these phenotypes provide valuable readouts for validation.

What are optimal methods for immunolocalization of NUP170?

When performing immunofluorescence to detect NUP170:

• Fixation: Use 4% paraformaldehyde for 15-20 minutes at room temperature to preserve nuclear envelope structure.

• Permeabilization: A gentle detergent treatment with 0.2% Triton X-100 is recommended to maintain nuclear pore integrity while allowing antibody access.

• Blocking: Use 3-5% BSA in PBS with 0.1% Tween-20 for at least 1 hour to reduce non-specific binding.

• Antibody concentration: Titrate primary NUP170 antibodies (typically starting at 1:200-1:1000 dilution) to optimize signal-to-noise ratio.

• Controls: Always include a no-primary antibody control and, if possible, a NUP170-depleted sample as a negative control.

• Co-localization markers: Consider co-staining with other nuclear pore markers (like mAb414 that recognizes FG-nucleoporins) to confirm proper NPC localization.

NUP170 typically appears as a punctate rim staining around the nuclear envelope, consistent with its localization to nuclear pores .

How can I validate the specificity of a NUP170 antibody?

To ensure your NUP170 antibody is specific:

• Western blot analysis: Confirm a single band of approximately 170 kDa in wild-type samples that is absent or reduced in NUP170 knockdown/knockout samples.

• Immunoprecipitation followed by mass spectrometry: Verify that NUP170 is the predominant protein pulled down.

• Immunofluorescence in control vs. NUP170-depleted cells: Demonstrate loss of nuclear envelope staining pattern in depleted cells.

• Epitope competition assay: Pre-incubate the antibody with excess purified epitope peptide to block specific binding sites before immunostaining.

• Domain-specific validation: If using antibodies against specific domains, test localization patterns in cells expressing only the N-terminal or C-terminal domains of NUP170 to confirm domain-specific recognition .

What experimental approaches can reveal NUP170's interaction with other proteins?

To study NUP170's protein interactions:

• Co-immunoprecipitation (Co-IP): Use NUP170 antibodies to pull down protein complexes, followed by western blot or mass spectrometry to identify interaction partners. This approach has successfully identified interactions between NUP170 and proteins like the Ctf18-RFC complex .

• Proximity labeling: BioID or APEX2 fusions to NUP170 can identify proteins in close proximity at the nuclear pore.

• Yeast two-hybrid screens: Can reveal direct protein-protein interactions but may miss interactions dependent on the NPC context.

• Fluorescence resonance energy transfer (FRET): For studying interactions in intact cells.

• Split-GFP complementation: To visualize interaction sites within cells.

• Chromatin immunoprecipitation (ChIP): To study NUP170's association with chromatin regions, particularly at subtelomeric regions involved in gene silencing .

How can I distinguish between the functions of NUP170's N-terminal and C-terminal domains?

To dissect domain-specific functions:

Research has shown that overexpression of just the C-terminal domain in nup170Δ cells is toxic and causes accumulation of several nucleoporins in cytoplasmic foci, revealing its crucial role in NPC assembly .

How can ChIP-seq with NUP170 antibodies reveal its role in chromatin organization?

To investigate NUP170's association with chromatin:

• Crosslinking optimization: Use a dual crosslinking approach with both formaldehyde (1%) and a protein-protein crosslinker like DSG or EGS to capture transient interactions between NUP170 and chromatin.

• Sonication parameters: Optimize sonication conditions to generate chromatin fragments of 200-500bp for high-resolution mapping.

• Immunoprecipitation controls: Include IgG control, input samples, and ideally a NUP170-depleted control.

• Data analysis: Focus particularly on subtelomeric regions, where NUP170 has been shown to regulate gene silencing .

• Validation experiments: Confirm ChIP-seq findings with ChIP-qPCR at specific loci, especially subtelomeric genes like COS4, COS10, GIT1, and TOG1 that show altered expression in nup170Δ cells .

• Integration with expression data: Correlate ChIP-seq binding data with RNA-seq in wild-type vs. nup170Δ cells to link chromatin binding with transcriptional effects.

This approach has revealed that NUP170 associates with subtelomeric chromatin regions and influences gene silencing at these locations .

What techniques can reveal NUP170's role in PCNA loading and subtelomeric silencing?

To explore this recently discovered function:

• PCNA chromatin association assays: Use chromatin fractionation followed by western blotting to quantify PCNA levels on chromatin in wild-type vs. nup170Δ cells.

• ChIP-qPCR for PCNA: Compare PCNA enrichment at specific genomic loci between wild-type and nup170Δ cells.

• Genetic interaction studies: Combine nup170Δ with mutations in genes encoding PCNA loaders (Ctf18-RFC) or unloaders (Elg1) and assess effects on subtelomeric silencing.

• RT-qPCR of subtelomeric genes: Measure expression of genes like COS4, COS10, GIT1, and TOG1 to quantify silencing effects.

• Proximity ligation assay (PLA): Detect in situ interactions between NUP170 and components of the PCNA loading/unloading machinery.

Research has demonstrated that in nup170Δ cells, PCNA levels on DNA are reduced, resulting in loss of subtelomeric gene silencing. Remarkably, increasing PCNA levels by deleting ELG1 (required for PCNA unloading) rescued silencing defects in nup170Δ cells .

How can I resolve high background when using NUP170 antibodies in immunofluorescence?

High background is a common issue with nuclear pore complex antibodies:

• Increase blocking time and concentration: Use 5% BSA for 2 hours or overnight at 4°C.

• Add 0.1-0.3M NaCl to antibody dilution buffer to reduce non-specific ionic interactions.

• Pre-adsorb antibodies against fixed, permeabilized cells lacking NUP170 expression.

• Use monovalent Fab fragments instead of complete IgG molecules to reduce cross-linking and background.

• Try different fixation methods: If paraformaldehyde gives high background, cold methanol fixation might work better for NUP170 detection.

• Consider using recombinant antibody fragments with higher specificity for the target epitope.

• For tissues or complex samples, adding normal serum (5-10%) from the same species as the secondary antibody can reduce background.

How should I interpret conflicting localization data between NUP170 antibodies?

When different NUP170 antibodies show discrepant localization patterns:

• Epitope mapping: Determine the exact epitopes recognized by each antibody, as they might target different domains with distinct localizations or accessibility.

• Domain-specific functions: The N-terminal and C-terminal domains of NUP170 have different functions and potentially different localizations under certain conditions .

• Conformational changes: NUP170 may undergo conformational changes that mask certain epitopes in specific cellular contexts.

• Sample preparation effects: Different fixation and permeabilization methods can affect epitope accessibility.

• Cross-reactivity: Some antibodies might cross-react with the homologous protein NUP157.

• Cell cycle-dependent changes: NUP170 localization or epitope accessibility might vary during cell cycle progression.

• Validate with tagged constructs: Compare antibody staining patterns with GFP-tagged NUP170 localization to resolve discrepancies.

What experimental approaches can resolve contradictions in NUP170 function between different studies?

When confronted with conflicting functional data:

• Cell type differences: Determine if discrepancies arise from using different cell types or organisms (yeast vs. mammalian systems).

• Knockout vs. knockdown comparisons: Complete knockout may reveal different phenotypes than partial depletion due to compensation mechanisms.

• Redundancy effects: Consider the compensatory role of NUP157 or other nucleoporins in different experimental systems .

• Genetic background influences: The effect of nup170Δ can vary depending on the presence of mutations in other genes, particularly those involved in nuclear transport or chromatin organization .

• Quantitative vs. qualitative differences: Some phenotypes may appear contradictory but actually represent different severity levels of the same underlying defect.

• Temporal factors: Acute vs. chronic depletion of NUP170 may yield different results due to adaptive responses.

• Direct vs. indirect effects: Determine whether observed phenotypes are direct consequences of NUP170 loss or secondary effects from disruption of nuclear transport.

How can I study the dynamics of NUP170 incorporation into nuclear pores?

To investigate NUP170 dynamics:

• Fluorescence recovery after photobleaching (FRAP): Using GFP-tagged NUP170 to measure turnover rates at nuclear pores.

• Single-molecule tracking: Monitor individual molecules of fluorescently tagged NUP170 to determine residence times and movement patterns.

• Correlative light and electron microscopy (CLEM): Combine fluorescence microscopy of tagged NUP170 with electron microscopy to visualize its exact position within the NPC structure.

• Optogenetic approaches: Use light-inducible dimerization systems to trigger recruitment or displacement of NUP170 from NPCs.

• Live-cell imaging during mitosis: Track NUP170 during nuclear envelope breakdown and reassembly to understand its role in post-mitotic NPC formation.

• Inducible expression systems: Measure the kinetics of NPC assembly after induced expression of NUP170 in nup170Δ cells.

• Super-resolution microscopy: Techniques like STORM or PALM can reveal nanoscale organization of NUP170 within the NPC structure.

What new approaches could reveal how NUP170 influences gene expression and chromatin organization?

To explore these emerging functions:

• Hi-C analysis in nup170Δ cells: Examine changes in 3D genome organization, particularly at subtelomeric regions.

• Integration of ChIP-seq with ATAC-seq: Correlate NUP170 binding with changes in chromatin accessibility.

• Single-cell RNA-seq in heterogeneous populations: Determine if NUP170-dependent gene silencing shows cell-to-cell variability.

• Targeted DamID: Use NUP170 fused to DNA adenine methyltransferase to identify genomic regions that interact with NUP170 at the nuclear periphery.

• In situ Hi-C: Map chromatin organization at the nuclear periphery and its dependence on NUP170.

• Proteomics of isolated chromatin domains: Identify proteins recruited to or displaced from subtelomeric regions in the presence or absence of NUP170.

• CRISPR screening for genetic interactors: Identify genes that modify NUP170-dependent phenotypes to discover new functional relationships.